Copyright Reports & Markets. All rights reserved.

Global Overactive Bladder Treatment Drug Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Overactive Bladder Treatment Drug Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Anticholinergics
      • 1.4.3 Solifenacin
      • 1.4.4 Oxybutynin
      • 1.4.5 Darifenacin
      • 1.4.6 Fesoterodine
      • 1.4.7 Tolterodine
      • 1.4.8 Trospium
      • 1.4.9 Others
    • 1.5 Market by Application
      • 1.5.1 Global Overactive Bladder Treatment Drug Market Share by Application (2014-2025)
      • 1.5.2 Idiopathic Bladder Overactivity
      • 1.5.3 Neurogenic Bladder Overactivity
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Overactive Bladder Treatment Drug Market Size
    • 2.2 Overactive Bladder Treatment Drug Growth Trends by Regions
      • 2.2.1 Overactive Bladder Treatment Drug Market Size by Regions (2014-2025)
      • 2.2.2 Overactive Bladder Treatment Drug Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Overactive Bladder Treatment Drug Market Size by Manufacturers
      • 3.1.1 Global Overactive Bladder Treatment Drug Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Overactive Bladder Treatment Drug Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Overactive Bladder Treatment Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Overactive Bladder Treatment Drug Key Players Head office and Area Served
    • 3.3 Key Players Overactive Bladder Treatment Drug Product/Solution/Service
    • 3.4 Date of Enter into Overactive Bladder Treatment Drug Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Overactive Bladder Treatment Drug Market Size by Type (2014-2019)
    • 4.2 Global Overactive Bladder Treatment Drug Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Overactive Bladder Treatment Drug Market Size (2014-2019)
    • 5.2 Overactive Bladder Treatment Drug Key Players in United States
    • 5.3 United States Overactive Bladder Treatment Drug Market Size by Type
    • 5.4 United States Overactive Bladder Treatment Drug Market Size by Application

    6 Europe

    • 6.1 Europe Overactive Bladder Treatment Drug Market Size (2014-2019)
    • 6.2 Overactive Bladder Treatment Drug Key Players in Europe
    • 6.3 Europe Overactive Bladder Treatment Drug Market Size by Type
    • 6.4 Europe Overactive Bladder Treatment Drug Market Size by Application

    7 China

    • 7.1 China Overactive Bladder Treatment Drug Market Size (2014-2019)
    • 7.2 Overactive Bladder Treatment Drug Key Players in China
    • 7.3 China Overactive Bladder Treatment Drug Market Size by Type
    • 7.4 China Overactive Bladder Treatment Drug Market Size by Application

    8 Japan

    • 8.1 Japan Overactive Bladder Treatment Drug Market Size (2014-2019)
    • 8.2 Overactive Bladder Treatment Drug Key Players in Japan
    • 8.3 Japan Overactive Bladder Treatment Drug Market Size by Type
    • 8.4 Japan Overactive Bladder Treatment Drug Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Overactive Bladder Treatment Drug Market Size (2014-2019)
    • 9.2 Overactive Bladder Treatment Drug Key Players in Southeast Asia
    • 9.3 Southeast Asia Overactive Bladder Treatment Drug Market Size by Type
    • 9.4 Southeast Asia Overactive Bladder Treatment Drug Market Size by Application

    10 India

    • 10.1 India Overactive Bladder Treatment Drug Market Size (2014-2019)
    • 10.2 Overactive Bladder Treatment Drug Key Players in India
    • 10.3 India Overactive Bladder Treatment Drug Market Size by Type
    • 10.4 India Overactive Bladder Treatment Drug Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Overactive Bladder Treatment Drug Market Size (2014-2019)
    • 11.2 Overactive Bladder Treatment Drug Key Players in Central & South America
    • 11.3 Central & South America Overactive Bladder Treatment Drug Market Size by Type
    • 11.4 Central & South America Overactive Bladder Treatment Drug Market Size by Application

    12 International Players Profiles

    • 12.1 Astellas Pharma, Inc. (Japan)
      • 12.1.1 Astellas Pharma, Inc. (Japan) Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Overactive Bladder Treatment Drug Introduction
      • 12.1.4 Astellas Pharma, Inc. (Japan) Revenue in Overactive Bladder Treatment Drug Business (2014-2019)
      • 12.1.5 Astellas Pharma, Inc. (Japan) Recent Development
    • 12.2 Pfizer, Inc. (U.S.)
      • 12.2.1 Pfizer, Inc. (U.S.) Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Overactive Bladder Treatment Drug Introduction
      • 12.2.4 Pfizer, Inc. (U.S.) Revenue in Overactive Bladder Treatment Drug Business (2014-2019)
      • 12.2.5 Pfizer, Inc. (U.S.) Recent Development
    • 12.3 Teva Pharmaceutical Industries Limited (Israel)
      • 12.3.1 Teva Pharmaceutical Industries Limited (Israel) Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Overactive Bladder Treatment Drug Introduction
      • 12.3.4 Teva Pharmaceutical Industries Limited (Israel) Revenue in Overactive Bladder Treatment Drug Business (2014-2019)
      • 12.3.5 Teva Pharmaceutical Industries Limited (Israel) Recent Development
    • 12.4 Allergan, Plc (Ireland)
      • 12.4.1 Allergan, Plc (Ireland) Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Overactive Bladder Treatment Drug Introduction
      • 12.4.4 Allergan, Plc (Ireland) Revenue in Overactive Bladder Treatment Drug Business (2014-2019)
      • 12.4.5 Allergan, Plc (Ireland) Recent Development
    • 12.5 Medtronic plc (Ireland)
      • 12.5.1 Medtronic plc (Ireland) Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Overactive Bladder Treatment Drug Introduction
      • 12.5.4 Medtronic plc (Ireland) Revenue in Overactive Bladder Treatment Drug Business (2014-2019)
      • 12.5.5 Medtronic plc (Ireland) Recent Development
    • 12.6 Mylan N.V. (U.S.)
      • 12.6.1 Mylan N.V. (U.S.) Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Overactive Bladder Treatment Drug Introduction
      • 12.6.4 Mylan N.V. (U.S.) Revenue in Overactive Bladder Treatment Drug Business (2014-2019)
      • 12.6.5 Mylan N.V. (U.S.) Recent Development
    • 12.7 Endo International plc (Ireland)
      • 12.7.1 Endo International plc (Ireland) Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Overactive Bladder Treatment Drug Introduction
      • 12.7.4 Endo International plc (Ireland) Revenue in Overactive Bladder Treatment Drug Business (2014-2019)
      • 12.7.5 Endo International plc (Ireland) Recent Development
    • 12.8 Hisamitsu Pharmaceutical Co., Inc. (Japan)
      • 12.8.1 Hisamitsu Pharmaceutical Co., Inc. (Japan) Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Overactive Bladder Treatment Drug Introduction
      • 12.8.4 Hisamitsu Pharmaceutical Co., Inc. (Japan) Revenue in Overactive Bladder Treatment Drug Business (2014-2019)
      • 12.8.5 Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Development
    • 12.9 Sanofi (France)
      • 12.9.1 Sanofi (France) Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Overactive Bladder Treatment Drug Introduction
      • 12.9.4 Sanofi (France) Revenue in Overactive Bladder Treatment Drug Business (2014-2019)
      • 12.9.5 Sanofi (France) Recent Development
    • 12.10 Apotex, Inc. (Canada)
      • 12.10.1 Apotex, Inc. (Canada) Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Overactive Bladder Treatment Drug Introduction
      • 12.10.4 Apotex, Inc. (Canada) Revenue in Overactive Bladder Treatment Drug Business (2014-2019)
      • 12.10.5 Apotex, Inc. (Canada) Recent Development
    • 12.11 Cogentix Medical, Inc. (U.S.)
    • 12.12 Aurobindo Pharma Limited (India)

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      In 2018, the global Overactive Bladder Treatment Drug market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2019-2025.

      This report focuses on the global Overactive Bladder Treatment Drug status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Overactive Bladder Treatment Drug development in United States, Europe and China.

      The key players covered in this study
      Astellas Pharma, Inc. (Japan)
      Pfizer, Inc. (U.S.)
      Teva Pharmaceutical Industries Limited (Israel)
      Allergan, Plc (Ireland)
      Medtronic plc (Ireland)
      Mylan N.V. (U.S.)
      Endo International plc (Ireland)
      Hisamitsu Pharmaceutical Co., Inc. (Japan)
      Sanofi (France)
      Apotex, Inc. (Canada)
      Cogentix Medical, Inc. (U.S.)
      Aurobindo Pharma Limited (India)

      Market segment by Type, the product can be split into
      Anticholinergics
      Solifenacin
      Oxybutynin
      Darifenacin
      Fesoterodine
      Tolterodine
      Trospium
      Others

      Market segment by Application, split into
      Idiopathic Bladder Overactivity
      Neurogenic Bladder Overactivity

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Overactive Bladder Treatment Drug status, future forecast, growth opportunity, key market and key players.
      To present the Overactive Bladder Treatment Drug development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Overactive Bladder Treatment Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now